Sec Form 4 Filing - Kwan Rudolf @ Athenex, Inc. - 2022-04-22

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Kwan Rudolf
2. Issuer Name and Ticker or Trading Symbol
Athenex, Inc. [ ATNX]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
EVP, Chief Medical Officer
(Last) (First) (Middle)
C/O ATHENEX, INC.,, 1001 MAIN STREET, SUITE 600
3. Date of Earliest Transaction (MM/DD/YY)
04/22/2022
(Street)
BUFFALO, NY14203
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 04/22/2022 A 7,986( 1 ) A $ 0.6136 193,572 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $ 4.55 01/02/2016 01/02/2023 Common Stock 96,000 96,000 D
Stock Option (Right to Buy) $ 4.55 05/13/2018 05/13/2023 Common Stock 48,000 48,000 D
Stock Option (Right to Buy) $ 4.55 02/12/2018 02/12/2024 Common Stock 120,000 120,000 D
Stock Option (Right to Buy) $ 4.55 06/12/2017 06/12/2024 Common Stock 48,000 48,000 D
Stock Option (Right to Buy) $ 5.5 12/16/2018 12/16/2024 Common Stock 200,000 200,000 D
Stock Option (Right to Buy) $ 7.5 05/22/2019 05/22/2025 Common Stock 120,000 120,000 D
Stock Option (Right to Buy) $ 11 06/13/2020 06/13/2027 Common Stock 140,000 140,000 D
Stock Option (Right to Buy) $ 17.3 03/27/2022 03/27/2028 Common Stock 120,000 120,000 D
Stock Option (Right to Buy) $ 13.17 ( 2 ) 02/28/2029 Common Stock 120,000 120,000 D
Stock Option (Right to Buy) $ 12.45 ( 3 ) 06/05/2030 Common Stock 140,000 140,000 D
Stock Option (Right to Buy) $ 3.8 ( 4 ) 08/03/2031 Common Stock 70,000 70,000 D
Restricted Stock Units ( 5 ) ( 6 ) ( 6 ) Common Stock 70,000 70,000 D
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Kwan Rudolf
C/O ATHENEX, INC.,
1001 MAIN STREET, SUITE 600
BUFFALO, NY14203
EVP, Chief Medical Officer
Signatures
/s/ Steven Adams, Attorney-in-Fact 04/29/2022
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Shares purchased from the Issuer under a Salary Deduction and Stock Purchase Agreement at the Nasdaq Official Closing Price on the date of purchase.
( 2 )This option vests in four equal annual installments beginning on February 28, 2020.
( 3 )This option vests in four equal annual installments beginning on June 5, 2021.
( 4 )The option vests in four equal annual installments beginning on August 3, 2022.
( 5 )Each restricted stock unit represents a contingent right to receive one share of stock.
( 6 )The restricted stock units vest in four equal annual installments beginning on August 3, 2022.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.